Trends and determinants of choline alfoscerate use in newly diagnosed Alzheimer's disease patients in Korea.

ABSTRACT:

Background

Choline alfoscerate, a cholinergic precursor, is widely used in Korea for dementia-related symptoms and is covered by national health insurance (NHI). This study investigates the utilization trends and factors influencing choline alfoscerate prescription in newly diagnosed Alzheimer's disease (AD) patients using real-world data.

Methods

We analyzed data from the Health Insurance Review and Assessment Service (HIRA) for patients aged 60 years and older who were newly diagnosed with AD between 2012 and 2019. Patients with prescriptions for acetylcholinesterase inhibitors (AChEIs) or memantine within 60 days of diagnosis were included. Choline alfoscerate utilization was defined as prescriptions within 60 days of initial diagnosis. Factors influencing its use were id

SUBMITTER: Kim YH 

PROVIDER: S-EPMC11694518 | biostudies-literature | 2024 Oct-Dec

REPOSITORIES: biostudies-literature